November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.
April 2025 in “The Journal of Dermatology” This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.
July 2026 in “Journal of the American Academy of Dermatology” Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.
December 2025 in “International Journal of Dermatology” This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.
19 citations
,
August 2019 in “Dermatologic therapy” This review discusses the use of Janus kinase inhibitors for alopecia areata and reports promising short-term efficacy but low-quality evidence, highlighting the need for further research to confirm long-term safety and effectiveness.
